Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-04494700 (TTP488), PF-04494700
PF-04494700- Low Dose Arm · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| PF-04494700 (TTP488) | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Low Dose Arm | EXPERIMENTAL | - |
| High Dose Arm | EXPERIMENTAL | - |
| Placebo Control | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04494700 | DRUG | 15 mg for 6 days followed by daily dosing of 5mg |
| Placebo | DRUG | Placebo |
| PF-04494700 (TTP488) | DRUG | 60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication |
| PF-04494700 - Low Dose Arm | DRUG | 30 mg loading dose for 6 days, followed by 10 mg daily |
| PF-04494700 - High Dose Arm | DRUG | 60 mg loading dose for 6 days, followed by 20 mg daily |
| Placebo Comparator | DRUG | Matching placebo. |
Inclusion Criteria: * Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening. * Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization Exclusion Criteria: * Current evidence or history of neurological, psych...
Top 20 of 30 competitors
PF-04494700- Low Dose Arm refers to the low-dose treatment group of PF-04494700, an investigational small molecule developed by Pfizer, Inc. (ticker: PFE). It was studied in Phase 2 clinical trials for Alzheimer's disease and diabetic nephropathy. The low-dose arm specifically evaluates a reduced dosage regimen of the drug.
PF-04494700- Low Dose Arm was studied for the treatment of mild to moderate Alzheimer's disease and diabetic nephropathy. These are the two indications explored in its clinical development program. The drug remains investigational and is not approved for any use.
Pfizer, Inc. (ticker: PFE) is the developer of PF-04494700- Low Dose Arm. Pfizer sponsored the Phase 2 clinical trials evaluating this low-dose regimen in Alzheimer's disease and diabetic nephropathy.
PF-04494700- Low Dose Arm is in Phase 2 clinical development. All trials for this drug candidate have been completed, and no active trials are currently ongoing. It is an investigational therapy and has not been approved by the FDA.
PF-04494700- Low Dose Arm has been evaluated in three completed Phase 2 trials: NCT00566397 in mild to moderate Alzheimer's disease (402 patients), NCT00287183 in type 2 diabetes with persistent albuminuria (110 patients), and NCT00141661 in Alzheimer's patients (67 patients). Total enrollment across these trials was 469 participants.
Yes, PF-04494700- Low Dose Arm is a specific dosing group of PF-04494700, also known as TTP488. The low-dose arm refers to the lower dosage regimen tested within the broader clinical program for this drug candidate.